Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$0.17
$0.19
$0.16
$1.09
$4.96M0.191.89 million shs47,123 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$5.45
-2.7%
$4.52
$2.25
$7.99
$138.65M0.53225,364 shs190,738 shs
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$0.48
-36.9%
$0.38
$0.13
$1.00
$12.82M0.29182,400 shs1.58 million shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
+0.42%+1.63%-9.03%-24.19%-79.48%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
+1.63%+18.39%+19.66%+30.23%-5.08%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-15.65%+44.84%+130.99%+242.19%+16.94%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.0349 of 5 stars
3.52.00.00.03.14.20.6
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.173 of 5 stars
0.03.00.00.01.12.50.0
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$18.50239.45% Upside
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A

Current Analyst Ratings

Latest NVCN, DCTH, GCTK, and AFIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $20.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$7.16M0.69N/AN/A($0.03) per share-5.56
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$2.07M66.98N/AN/A$0.72 per share7.57
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A$0.15 per shareN/A
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
-$81.66M-$1.24N/AN/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-$7.10M-$0.37N/AN/AN/A-172.38%-127.42%5/10/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A

Latest NVCN, DCTH, GCTK, and AFIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/A-$0.10-$0.10-$0.10N/AN/A
3/26/2024Q4 23
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
1.10
2.44
2.22
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
2.26
2.06
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.06
3.22
3.22
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
56.91%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
10.92%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%

Insider Ownership

CompanyInsider Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
3.50%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.94%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
17.70%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
23029.72 million28.68 millionOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
7625.44 million20.88 millionOptionable
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
626.76 million22.02 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable

NVCN, DCTH, GCTK, and AFIB Headlines

SourceHeadline
Top Small-Cap Stocks for May 2023 - InvestopediaTop Small-Cap Stocks for May 2023 - Investopedia
news.google.com - May 13 at 9:38 AM
FDA accepts application for Roches Vabysmo for the - GlobeNewswireFDA accepts application for Roche's Vabysmo for the - GlobeNewswire
news.google.com - May 9 at 2:18 AM
New treatment option opens avenues in geographic atrophy - HealioNew treatment option opens avenues in geographic atrophy - Healio
news.google.com - May 8 at 9:18 PM
Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.comPachychoroid neovasculopathy has clinical properties that differ ... - Nature.com
news.google.com - May 8 at 9:18 PM
The NOD audit provides data and insights for the management for ... - Modern RetinaThe NOD audit provides data and insights for the management for ... - Modern Retina
news.google.com - May 8 at 9:18 PM
Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire
news.google.com - May 8 at 4:17 PM
Heart valve repair and replacement devices market size to grow by ... - BenzingaHeart valve repair and replacement devices market size to grow by ... - Benzinga
news.google.com - May 5 at 9:03 PM
ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times
news.google.com - May 5 at 4:02 PM
Faricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Press
news.google.com - May 5 at 12:24 AM
Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe
news.google.com - May 5 at 12:24 AM
STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine
news.google.com - May 4 at 7:24 PM
The NOD audit: Insights into the current state of management for ... - Nature.comThe NOD audit: Insights into the current state of management for ... - Nature.com
news.google.com - May 4 at 8:40 AM
On the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe
news.google.com - May 3 at 10:56 AM
Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars
news.google.com - April 28 at 3:22 PM
Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network
news.google.com - April 28 at 10:22 AM
Low-vision services improve vision, quality of life in patients with ... - HealioLow-vision services improve vision, quality of life in patients with ... - Healio
news.google.com - April 28 at 10:22 AM
New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire
news.google.com - April 25 at 6:55 PM
New treatment tackles both forms of AMD - Ophthalmology TimesNew treatment tackles both forms of AMD - Ophthalmology Times
news.google.com - April 25 at 6:55 PM
Price Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars
news.google.com - April 25 at 1:32 AM
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance
news.google.com - April 25 at 1:32 AM
Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotechAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotech
news.google.com - April 24 at 3:16 PM
Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular BusinessReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business
news.google.com - April 24 at 3:16 PM
Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics IndustryBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry
news.google.com - April 21 at 4:24 PM
The Future of the Structural Heart Disease Intervention Devices ... - Digital JournalThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journal
news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acutus Medical logo

Acutus Medical

NASDAQ:AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.
Delcath Systems logo

Delcath Systems

NASDAQ:DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
GlucoTrack logo

GlucoTrack

NASDAQ:GCTK
GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.